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HLA DRB1*02 and its subtypes predispose individuals for a far-advanced sputum-positive pulmonary
tuberculosis transcending ethnic boundaries. Mycobacterium bovis BCG does not afford the desired protection
against adult pulmonary tuberculosis, and a spectrum of immune reactivity exists in controls and hospital
contacts. All of these findings have been identified and demonstrated in areas of endemicity. Skewing of
immunity from protective to pathogenic may involve a shift in the Th1-Th2 paradigm. To elaborate these ideas,
we studied gamma interferon (IFN-g), interleukin-4 (IL-4), and IL-10 cytokine expression in 71 adult pulmo-
nary tuberculosis patients and 74 controls from areas of endemicity in south India by 48-h microculture and
reverse transcription-PCR. Most of the patients and controls expressed IFN-g de novo, and in the presence of
purified protein derivative (PPD), all of them expressed significantly higher levels of IFN-g, suggesting a
PPD-specific recall memory. HLA DRB1* allele-dependent IFN-g expression was identified only in controls,
suggesting a skewing of the immune response in patients. In contrast to the case for IFN-g, only some patients
and controls expressed IL-4 or IL-10 (Th2 profile); thus, the Th1 profile was identifiable only by a nonexpres-
sion of IL-4 or IL-10 in this area of endemicity. The Th2 profile was associated with HLA non-DRB1*02 and
BCG scar-negative status in patients, attributing a significant risk (odds ratio 5 2.074; 95% confidence
interval 5 0.612 to 7.07). It is possible that Mycobacterium tuberculosis (PPD)-specific IL-10 is expressed
preemptively in unvaccinated (BCG scar-negative) individuals with a non-DR2 genetic background by chronic
exposure in this area of endemicity and leads to pulmonary tuberculosis of adults.
Pulmonary tuberculosis has recently become a major prob-
lem in developed countries with the increase in the incidence
of tuberculosis in immunocompromised human immunodefi-
ciency virus-infected individuals and the increase in the emer-
gence of multidrug-resistant bacilli (3, 22); it has already been
recognized as the greatest killer and as a terminal disease in
developing countries. Mycobacterium bovis BCG is the only
prophylactic vaccine available as yet; BCG has been used
throughout the world, although with varying efficacies (17).
With the discovery of cytokines and the description of the
Th1-Th2 paradigm, the role of cytokines in tuberculosis patho-
genesis has been investigated. A standard dose of BCG induces
mycobacterium-specific gamma interferon (IFN-g), a CD4 re-
sponse, and antigen-specific cytotoxicity (27). However, the
development of the T-cell response itself is markedly influ-
enced by purified protein derivative (PPD) sensitivity before
vaccination (39). Studies on mouse models have equated Th1
to protective, cell-mediated immunity and Th2 to disease sta-
tus (2, 32). The role of interleukin-4 (IL-4) and IL-10 in mod-
ulating IFN-g expression has recently been described; trans-
genic and gene knockout mouse models have shown a
suppression of Th1-like T-cell responses by IL-10 (21, 49). For
humans, no concrete evidence relating Th2 to disease status
has yet been described.
Our understanding of the role of host immunogenetics in
infectious diseases is also limited; both major histocompatibil-
ity complex (MHC) and non-MHC genes have been implicated
(6, 20a, 23). Earlier studies on HLA association with pulmo-
nary tuberculosis did not lead to any consensus (35). With the
discovery of MHC class II, HLA DR2 associations in pulmo-
nary tuberculosis have been amply confirmed in countries
where the disease is endemic, such as India, Indonesia, and
Russia (7, 9, 25, 37, 38, 40, 41). Non-MHC genes such as those
for the mannose receptor, vitamin D receptors, and NRAMP1
have also been implicated in the disease process (6, 20a, 23).
Genome scan studies have suggested that the susceptibility is a
polygenic, multifactorial phenomenon (23). Nonetheless, these
genetic predispositions alone do not account for all of the cases
investigated in any study.
Many variables surround key genetic epidemiological pro-
cesses for Mycobacterium tuberculosis infection in regions of
endemicity. These include the age of the host, postinfection
disease progression, antigenic variation of the bacteria, micro-
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bial cross-reactivity, and environmental persistence and viru-
lence of the bacilli. Whether all three categories, i.e., host
genetic, immunological, and epidemiological factors, could be
a reason for the reduced efficacy of BCG in protection from
adult pulmonary tuberculosis in south India is a question of
interest (4, 17, 39). In the study reported here, we investigated
DRB1* and DQB1* alleles and PPD-RT23-recalled cytokine
expression in pulmonary tuberculosis patients and controls
from areas of endemicity and correlated them to the BCG
vaccination status.
MATERIALS AND METHODS
Study population. (i) Pulmonary tuberculosis patients. A total of 71 adult
pulmonary tuberculosis patients, born and brought up in the Madurai district,
south India, were studied in two samplings drawn from two different hospitals.
The first group, of 25 patients (mean age 6 standard error of the mean, 42.3 6
1.83 years; all males), were from the state-run TB Sanatorium, Thoppur, Madu-
rai, India, 13 km southwest of Madurai. All of the patients had advanced stages
of the disease, with sputum smears positive for acid-fast bacilli and X-ray positive
with bisubapical and bisubapical-apical infiltrates. These patients had been
treated for 6 to 61 days at the time of sampling. The second group, of 46 patients
(35.1 6 2.04 years; male/female ratio, 26:20), were from a state-run public
government hospital at Singampunari, 65 km northeast of Madurai. Patients with
presenting symptoms of pulmonary tuberculosis with radiological lesions and a
compatible clinical picture, with or without acid-fast bacilli in sputum smears,
were included in the study. These patients had been treated for 3 to 180 days at
the time of sampling. Both deltoids were examined for BCG scar status. Appro-
priate ethical clearance for the study from the institutional ethical committee and
informed consent from patients and controls were obtained.
(ii) Controls from areas of endemicity. Seventy-four controls from areas of
endemicity, consisting of members of the staff and students of the university who
were born and brought up in and around Madurai, were enrolled and studied in
two groups (n 5 25 and 49). The ages were 27.3 6 1.65 and 26.4 6 0.71 years,
respectively, and the male/female ratios were 18:7 and 29:20, respectively. Both
deltoids were examined for BCG scar status.
Antigen. PPD-RT23 without preservative, at a concentration of 50,000 U per
ml, was a gift from the BCG Vaccine Laboratory, Guindy, Chennai, India. A final
concentration of 100 U/ml of culture medium was used.
MHC class II genotyping. HLA-DRB1* and HLA-DQB1* genotyping of the
patients and controls were performed by the PCR–sequence-specific oligo probe
(SSOP) method, employing XI IHWC primers and probes as described else-
where (38).
Short-term cultures. Three to 5 milliliters of peripheral blood was obtained
from each donor in heparin vacutainers (455 051; Greiner, Frickenhausen, Ger-
many) and moved to the laboratory, and cultures were set up the same day.
The whole-blood culture technique described by Petrovsky and Harrison (33)
was adapted; it required a smaller volume of blood (46). In short, 50 ml of
heparinized whole blood, diluted to 200 ml with RPMI 1640 medium and anti-
biotics, was cultured for 48 h in 96-well U-bottom tissue culture plate (655 180;
Greiner). RPMI 1640 medium (31870-025; Life Technologies, Gibco-BRL,
Gaithersburg, Md.), supplemented with 6% pooled human AB serum (88-17-20-
013; Baxter Healthcare Ltd., Norfolk, United Kingdom), 2 mM glutamine (G-
1517; Sigma, St. Louis, Mo.), and antibiotics (S-9137 and P-3032; Sigma) was
used. Cultures were set up in quadruplicate, with or without PPD-RT23, and
incubated for 48 h in a CO2 incubator (3164; Forma Scientific, Marietta, Ohio)
set at 37°C with 5% CO2 and 95% humidity. Cultures were harvested; two of the
quadruplicates were pooled, one aliquot was processed further, and the other
aliquot was stored. In initial experiments, a dilution of 1:4 (whole blood in
medium) was found to be optimum, giving good b-actin and cytokine expression.
Optimum production of IFN-g, IL-4, and IL-10 was identified by 48 h after
stimulation, as already reported by many others (13, 34, 44).
Peripheral blood mononuclear cell (PBMC) cultures with 0.6 million cells per
well were set up in quadruplicate in 96-well U-bottom microtiter plates (655 180;
Greiner) according to standard procedures and as described above. The first
group of samples was studied by this PBMC culture method. Experiments on two
patients and four controls comparing whole-blood culture with PBMC culture
gave concordant results, validating the use of whole-blood culture: whenever an
individual expressed IFN-g and/or other cytokines in whole-blood culture, the
same cytokines were expressed in PBMC culture as well (14). Hence, the results
of the two experiments were pooled and analyzed.
RNA extraction and cDNA synthesis. Total RNA was extracted by a single-
step acid-phenol-chloroform extraction method (10), taking all of the necessary
precautions to wash the glass- and plasticware with 0.1% diethyl pyrocarbonate
(DEPC) (44170 3D; BDH Laboratory Supplies, Poole, United Kingdom). The
cultures were harvested, washed in cold phosphate-buffered saline, and imme-
diately suspended in 500 ml of lysis buffer and stored frozen at 270°C. To extract
total RNA, the lysates were thawed and processed further as described elsewhere
(10). RNA pellets were finally washed with 80% ethanol, dried, and suspended
in 8 ml of DEPC water. The samples were primed with 1 mg of oligo(dT) primer
(27-7858-02; Pharmacia Biotech) at 65°C for 10 min and cooled on ice, and
cDNA was synthesized in a block heater set at 37°C (QBT1; Grant Instruments,
Cambridge, United Kingdom) (16). The samples were finally denatured at 95°C
for 5 min, cooled on crushed ice, and diluted to 100 ml using DEPC water.
PCR to identify cytokine genes. Five microliters of the cDNA templates in a
25–ml PCR mixture were used to identify each cytokine gene. The primer se-
quences for b-actin, IFN-g, and IL-4 and the procedures of Ehlers and Smith
(16) were used. Primers for IL-10 were from Yamamura et al. (48). Primers were
made to order by Genosys, Cambridgeshire, United Kingdom, and the sequences
of primers were as follows: b-actin, 59TGACGGGGTCACCCACACTGTGCC
CATCTA39 (forward) and 59CTAGAAGCATTGCGGTGGACGATGGAGG
G39 (reverse) (product size, 661 bp); IFN-g, 59ATGAAATATACAAGTTATA
TCTTGGCTTT39 (forward) and 59GATGCTCTTCGACCTCGAAACAGCA
T39 (reverse) (product size, 501 bp); IL-4, 59ATGGGTCTCACCTCCCAACTG
CT39 (forward) and 59CGAACACTTTGAATATTTCTCTCTCAT39 (reverse)
(product size, 456 bp); and IL-10, 59ATGCCCCAAGCTGAGAACCAAGACC
CA39 (forward) and 59TCTCAAGGGGCTGGGTCAGCTATCCCA39 (re-
verse) (product size, 351 bp).
PCRs were performed in 0.2-ml PCR tubes or in PCR strips, using HYBAID
thermal cyclers (HBTR3 3CM 220). PCR cycles consisted of denaturation at
95°C for 45 s, annealing at 57.5°C for 45 s, and extension at 71.5°C for 90 s for
35 cycles, with a final extension of 72°C for 10 min. Twenty microliters of the
amplified products was electrophoresed at 100 V for 15 min in an agarose gel
with ethidium bromide and documented.
Quality control measures. To control the relative amount of products reverse
transcribed and to assess the amount of a given messenger in each sample,
concurrent PCR, electrophoresis, and measurements of the housekeeping gene
for b-actin and the specific cytokines were performed. The gels were visualized
under UV illumination and documented in an EDAS 120 system (154 9393;
Eastman Kodak Company, Rochester, N.Y.) (Fig. 1). The net band intensities
were measured as pixels, using Kodak Digital Science one-dimensional image
analysis software. To avoid inter- and intraexperimental variations, PCR on each
sample was repeated twice and assessed for concordance, and the average was
used for analysis. The net intensity of cytokine bands was normalized to the
intensity of b-actin bands of the given sample and expressed as a percentage of
FIG. 1. Photograph of a 1.5% agarose gel showing b-actin, IFN-g,
IL-4, and IL-10 bands identified by RT-PCR. Fifty microliters of whole
blood from each patient was diluted to 200 ml using RPMI 1640 and
cultured in duplicate in the absence (lanes 1 to 4) or in the presence
(lanes 5 to 8) of PPD-RT23 (100 U/ml) at 37°C in a CO2 incubator.
After 48 h, cultures were harvested, duplicates were pooled, total RNA
was extracted, and cDNA was synthesized and diluted to 100 ml. Five
microliters each of this cDNA was used as a template to amplify the
b-actin, IFN-g, IL-4, or IL-10 gene using sequence-specific primers.
The results were documented in a Kodak EDAS 120 system, and band
intensity was measured as pixels. The cytokine band intensity was
normalized to the b-actin band intensity using the formula net intensity
of cytokine/net intensity of b-actin 3 100. Lane M, standard marker
(f174 digested with HaeIII).
5636 DHEENADHAYALAN ET AL. INFECT. IMMUN.
b-actin intensity (cytokine band intensity 3 100/b -actin band intensity). PPD-
specific cytokine expression was obtained by deducting the percent b-actin values
of no-antigen controls from the percent b-actin values of the respective PPD-
induced experiments. An individual was considered negative for a given cytokine
when he or she did not produce the given cytokine in the presence and absence
of the antigen; the results were always confirmed by repeating the PCR for the
cytokine.
Validation of RT-PCR. In order to validate the reverse transcription-PCR
(RT-PCR) results obtained, RT-PCR and IFN-g ELISpot (enzyme-linked im-
munospot) cell titration experiments were performed simultaneously on the
same samples. ELISpots were obtained as per the instructions of the kit manu-
facturer (3420-2; MABTECH, Stockholm, Sweden). PBMCs from two healthy
volunteers were titrated from 0.1 to 2.5 million and cultured for 48 h for RT-PCR
and for 18 h for ELISpot analysis. The number of PBMCs in microcultures and
the net intensity of the RT-PCR bands (measured as pixels) compared well (r2 [P
value]: b-actin, 0.9789 [0.003]; IFN-g, 0.9979 [0.015]). In essence, over a wide
range of 10 dilutions between 0.1 to 2.5 million PBMCs, there was a linear
correlation between the RT-PCR band intensity and the number of PBMCs
used. Comparison of the RT-PCR band intensity and the number of IFN-g
ELISpots also correlated well in measuring the PPD-specific cytokine expression
and secretion in both donors (r2 5 0.8211 and 0.9292) (three dilutions tested).
Although the recent, real-time PCR is the best method to quantify expression, it
does not eliminate the inherent problems of measuring microvolumes and PCR
failures; with enough precautions and stringency, the average net intensity of
RT-PCR bands in the gel from repeat testing of a sample gives comparable
results and can best be employed for high throughput, as suggested elsewhere
(45).
Representative PCR products of IFN-g, IL-4, IL-10, and b-actin were further
sequenced using Big Dye terminator (catalog no. 4303149; Perkin-Elmer Ap-
plied Biosystems) in an ABI Prism 310 Genetic Analyzer (Perkin-Elmer Applied
Biosystems). The obtained sequences were compared with human IFN-g, IL-4,
and IL-10 sequences by Blast search. There were 97% identities for the forward
and reverse sequences of human IFN-g (accession no. emb/X01992.1), 91 and
89% for human IL-4 (NM 000589.1), 97 and 98% for human IL-10 (gb/
M57627.1), and 94% for human b-actin (emb/X00351.1).
Statistics. Comparison of various groups and subgroups and their cytokine
expression were analyzed by the paired t test, Wilcoxon signed rank test (WRT),
Mann-Whitney (MW) test, chi-square test, Mantel-Haenszel test, and odds ratio,
as applicable (42). Log-linear model analysis was employed to evaluate the
contributions of the HLA-DRB1*02 allele, BCG vaccination status, and IL-10
expression in disease development (20).
RESULTS
All of the controls and patients expressed PPD-specific
IFN-g but not IL-4 or IL-10. Peripheral blood samples from 44
controls from areas of endemicity and 43 pulmonary tubercu-
losis patients were cultured by the whole-blood culture method
in either the presence or absence of PPD-RT23 and assessed
for b-actin, IFN-g, IL-4, and IL-10 cytokine gene expression by
RT-PCR (Fig. 2). There was no difference in b-actin expres-
sion between the no-antigen control and PPD-RT23 cultures
of both controls from areas of endemicity and patients (data
not shown). However, 91% of the controls from areas of en-
demicity and 71% of the patients expressed a basal level of
FIG. 2. Comparison of basal (no-antigen control) and PPD-RT23-induced IFN-g, IL-4, and IL-10 expression in pulmonary tuberculosis
patients (n 5 43) and controls from areas of endemicity (n 5 44) from south India, studied by the whole-blood culture method. Fifty microliters
of whole blood diluted to 200 ml with RPMI medium was incubated for 48 h in the presence or absence of antigen in a CO2 incubator. Ninety-one
percent of the controls and 71% of the patients expressed IFN-g in the no-antigen control mixture, while all of the patients and controls expressed
IFN-g in the presence of PPD. In contrast, only certain individuals (responders, positives), produced IL-4 and/or IL-10 in either the presence or
absence of PPD. The values of cytokine expression (percentage of b-actin expression) of a sample in the absence and presence of PPD are
connected by lines, and the paired t test (PT) or WRT was applied to determine the significance.
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IFN-g in the no-antigen control cultures, while all of them
produced enhanced level of IFN-g following PPD stimulation
(paired t test, P , 0.0001; WRT, P , 0.0001). The data on the
duration of treatment in patients did show a nonsignificant
decline in IFN-g level (r2/P: IFN-g, 0.05/0.22; IL-4, 0.04/0.25;
IL-10, 0.006/0.66) and reduced variance; however, this did not
affect the positive status on a qualitative scale (see below).
In contrast to IFN-g, IL-4 and IL-10 were not expressed by
all of the controls from areas of endemicity and pulmonary
tuberculosis patients. Only 12 of 44 controls from areas of
endemicity and 21 of 43 patients responded to PPD; these
responders expressed an elevated level of IL-4 in the presence
of PPD (by WRT, P 5 0.0005 and P , 0.0001, respectively),
indicating an upregulation. IL-10 expression was observed in
21 of 44 controls from areas of endemicity and in 28 of 43
pulmonary tuberculosis patients. Paradoxically, the IL-10 ex-
pression decreased following PPD stimulation in many of them
(by WRT, P 5 0.0914 and P 5 0.037, respectively) (Fig. 2).
This suggested an active suppression by PPD exposure in vitro.
Thus, immunological memory specific to PPD was recalled in
48 h, and this was identifiable either by upregulation or by
active suppression of the cytokines in question.
HLA-DRB1* alleles influence IFN-g expression. In order to
determine whether the DRB1* allele correlates with the level
of IFN-g expression, the IFN-g levels in PPD cultures were
stratified and the data were analyzed. The results were signif-
icant in controls from areas of endemicity but not in patients.
The highest level of IFN-g was observed in controls with
DRB1*03 alleles (mean 6 standard error of the mean as
percent b-actin 5 189 6 32), and the lowest was observed in
controls with DRB1*08 alleles (93 6 11) (by the MW test, P 5
0.0023) (Table 1). DRB1*03, -07, -09, -10, and -1502 produced
above-median values of IFN-g, and all of their values were
significantly higher than those for controls with DRB1*08 (P 5
0.0023 [MW test], P 5 0.0187 [t test], P 5 0.0469 [t test], P 5
0.0527 [t test], and P 5 0.0382 [MW test], respectively).
DRB1*1501, -04, and -08 produced significantly lower levels of
IFN-g than the highest producer, DRB1*03 (P 5 0.0235 [t
test], P 5 0.038 [t test], and P 5 0.0023 [MW test], respective-
ly). PPD-specific IFN-g expression was different only between
DRB1*07 and DRB1*08 (136 6 21 and 75 6 13; P 5 0.0356
[t test]). However, the allele dependence of IFN-g in the PPD-
stimulated culture and PPD-specific IFN-g expression corre-
lated well (r2 5 0.7152; P 5 0.0076), suggesting an inherent
nature of this response. Analysis of the data based on DQB1*
alleles did not yield significant differences between various
alleles. Due to a smaller number of positives with IL-4 and
IL-10, it was not worthwhile to stratify and analyze these data.
HLA non-DRB1*02 status and BCG scar-negative status
are associated with IL-4 and IL-10 expression status in pul-
monary tuberculosis patients. The observations that the re-
sponding controls from areas of endemicity and patients ex-
pressed significant amounts of IL-4 and IL-10 and that IFN-g
was expressed by all of the individuals in this area of endemic-
ity led us to look for other parameters of susceptibility. In this
regard, HLA DRB1*02, an allele repeatedly confirmed to have
association with pulmonary tuberculosis (7, 9, 25, 37, 38), was
one of the candidates. The second one was BCG vaccination
status. It is known that BCG vaccination in India protects
infants but not adults from pulmonary tuberculosis (4, 44a);
there are many suggestions on how a BCG vaccine protecting
infants may be skewed in adults (17). The cytokine expression
status in 71 patients and 74 controls was thus studied qualita-
tively, and data were analyzed based on the above parameters
(Table 2).
Thirty-seven of the 71 patients were BCG scar negative and
IL-10 positive; this was significant in a two-by-two cross tabu-
lation (P 5 0.0099). Similarly, 36 patients were BCG scar
negative and IL-4 positive (P 5 0.0041), and 30 of them were
BCG scar negative and both IL-4 and IL-10 positive (P 5
0.0053). No such skewed distribution was found in controls
(Table 2). Many other parameters, such as age, sex, duration of
treatment, and caste of the subjects, did not yield meaningful
results.
Nested classification analysis of the three parameters, viz.,
DRB1*02 status, BCG status, and IL-10 status was applied to
study their interactions (20). All possible log-linear models,
starting from the model of DRB1*02 effect only to the model
TABLE 1. PPD-RT23-induced IFN-g expression and its HLA
DRB1p allele dependence in controls from areas of endemicity
DRB1* allele (na) PPD-specific IFN-g expression(mean 6 SEM)b
DRB1*1501 (19) ..........................................................128 6 9.8
DRB1*1502 (6) ............................................................143 6 20
DRB1*03 (7) ................................................................189 6 32
DRB1*04 (12) ..............................................................123 6 12
DRB1*06 (8) ................................................................134 6 24
DRB1*07 (8) ................................................................167 6 24
DRB1*08 (7) ................................................................ 93 6 11
DRB1*09 (3) ................................................................163 6 41
DRB1*10 (4) ................................................................150 6 29
a Number of samples with the indicated DRB1p allele.
bP values for significant differences between alleles are given in the text. No
significant differences were observed among patients.
TABLE 2. Correlation between BCG scar status and IL-10
and/or IL-4 expression status in pulmonary tuberculosis
patients and controls
Cytokine
status
No. with the indicated BCG status
Patients (n 5 71) Controls (n 5 74)
Negative Positive Negative Positive
IL-10
Negative 18 11 15 21
Positive 37 5 18 20
P 0.0099 0.6219
IL-4
Negative 19 12 18 29
Positive 36 4 15 12
P 0.0041 0.1505
IL-4 1 IL-10a
Negative 12 10 14 9
Positive 30 3 14 10
P 0.0053 0.2355
a Results where IL-4 and IL-10 were not both positive or both negative were
not counted, and hence n was 55 and 47 for patients and controls, respectively.
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involving interaction of (DRB1*02)(IL-10), (BCG)(IL-10),
and (DRB1*02)(BCG), were considered and tested for their
significance. A model involving (DRB1*02)(IL-10) and
(BCG)(IL-10) had the highest likelihood ratio probability, of
0.3711. The expected frequency of this log-linear model was
given by log eijk 5 m 1 l
D
i 1 l
B
j 1 l
I
k 1 l
DI
ik 1 l
BI
jk, where
eijk is the expected frequency of the cell (i, j, k) and D repre-
sents the factor DRB1*02, I represents the factor IL-10, and B
represents the factor BCG. The estimates of these parameters
were obtained, and the expected frequencies were calculated
according to the fitted model (Table 3). The differences be-
tween observed and expected frequencies were expressed as
standardized deviates (z values). All of the standardized devi-
ates were less than 1.96 (i.e., a probability of .0.05), and hence
the proposed model, (DRB1*02)(IL-10) and (BCG)(IL-10)
interactions, was validated. Similar characteristics were ob-
served with IL-4 as well; the standardized deviates were less
than 1.96 for the model (DRB1*02)(IL-4) and (BCG)(IL-4)
interactions. No such interactions were identified in controls.
Further analyses taking IL-10 as the explanatory variable
and disease status (patients and controls) as the outcome vari-
able with all cross combinations of DRB1*02 and BCG re-
vealed a significant odds ratio for non-DRB1*02, BCG scar-
negative and IL-10-positive patients and controls (odds ratio 5
2.07; 95% confidence interval 5 0.612 to 7.072) (Table 4).
Considering IL-4 as the explanatory variable, the odds ratio
was only 1.53 (confidence interval, 0.51 to 4.6).
DISCUSSION
The present study has brought out some important observa-
tions on the interplay of MHC, cytokines, and BCG vaccina-
tion (immune) status in pulmonary tuberculosis susceptibility
in this area of endemicity. First, a high background level and
PPD-recalled IFN-g expression observed in this area of ende-
micity could be attributed to the endemicity of typical and
atypical mycobacterial infections and the resultant subclinical
exposure. Second, a significant increase in PPD-recalled IFN-g
expression in both patients and controls irrespective of their
BCG status has indicated immunological memory resulting
from chronic exposure or disease, overriding the BCG vacci-
nation-induced immunity. The DRB1* allele dependence of
IFN-g expression identified only in controls from areas of
endemicity but not in patients has suggested that the IFN-g
expression is allele dependent and inherent and may be oblit-
erated in patients by the infection per se. Our preliminary
studies on ELISpot Pepscan with Esat-6 peptides show similar
MHC-restricted IFN-g ELISpots in controls from areas of
endemicity but not in pulmonary tuberculosis patients (S.
Vani, unpublished data). Thus, understanding the difference
between subclinical exposure and the infection per se in skew-
ing the course of the immune response and the epitope spec-
ificity of the immunological memory and immunopathogenesis
in this area of endemicity has become urgent.
Third, the nested classification analysis of the data has sug-
gested that many of the BCG scar-positive patients and con-
trols did not express IL-10 (11 of 16 patients and 21 of 41
controls) or IL-4 (12 of 16 patients and 29 of 41 controls); this
suggests a long-lasting memory of BCG vaccination identified
by Th2 cytokine nonexpression. This implies that BCG vacci-
nation induces a Th1 type of immunity in this area of ende-
micity but that this is of no use in protecting adults from
infection, reinfection, or reactivation. Further the expression
of Th2 cytokines IL-10 and IL-4 is dependent on non-
DRB1*02 and BCG scar-negative status in patients. It is pos-
sible that the Th2 profile of an individual is inherent: if an
individual had not been vaccinated during childhood and has a
non-DR2 phenotype, the chances of infection leading to clin-
ical disease as an adult are greater. It is interesting that (i)
TABLE 3. Nested classification analysis of three factors (DRB1p02, BCG, and IL-10 status) and their interactions
in pulmonary tuberculosis patients (n 5 71)
DRB1p02 status BCG scar status
IL-10-negative patients IL-10-positive patients
No. observed No. expected z valuea No. observed No. expected z value
Negative Negative 9 7.4 0.6 24 24.7 20.1
Positive 3 4.6 20.7 4 3.3 0.4
Positive Negative 9 10.6 20.5 13 12.3 0.2
Positive 8 6.4 0.6 1 1.7 20.5
a Standardized deviate (z value) 5 (observed 2 expected)/=expected.
TABLE 4. Comparison of the observed frequencies of IL-10 expression status in pulmonary tuberculosis patients and controls
and the probability of occurrence (odds ratio)
DRB1p02 status BCG scar status
Patients (n 5 71) Controls (n 5 74)
Odds ratioa 95% confidenceintervalNo. IL-10 negative No. IL-10 positive No. IL-10 negative No. IL-10 positive
Negative Negative 9 24 7 9 2.074 0.612–7.07
Positive 3 4 8 13 0.821 0.162–4.19
Positive Negative 9 13 8 9 1.284 1.282–0.37
Positive 8 1 13 7 0.054 0–0.53
a An odds ratio of 2.074 indicates that the IL-10 expression status was associated with DRB1p02-negative status and BCG scar status in patients.
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DRB1*02 and (ii) non-DRB1*02 but IL-10 account for 83% of
the cases.
It is essential to mention here that the BCG scar-negative
subjects reported in this study may include at least three
groups: those who were not BCG vaccinated, those who were
BCG vaccinated but did not develop the scar, and those who
were BCG vaccinated and developed the scar but lost the scar
over time (16a). Although BCG vaccination is mandatory in
India, the BCG scar prevalence is quite varied in our study
areas (unpublished observation). As identified elsewhere
(16a), it is possible that a proportion of the reported BCG
scar-negative patients and controls were really vaccinated.
However, in the present study, despite the possible heteroge-
neity of the BCG scar-negative group, we find a good correla-
tion of this group with non-DRB1*02 and IL-10 status.
It has become urgent to investigate how the endemicity of
infection may nullify the childhood protective immunity con-
ferred by BCG vaccination. Studies on animal models of in-
fectious diseases have shown that a Th1 profile is protective
and a Th2 profile is pathogenic. Although there is compelling
evidences that IFN-g is a protective cytokine in mouse tuber-
culosis (12, 18) and although IFN-g is maximally expressed at
the initial stages of infection and IL-4 is maximally expressed
after the infection has been contained (32), their value in
humans in an area of endemicity like India is not known. The
protective efficacy of DNA vaccines encoding M. tuberculosis
sequences is correlated to the emergence of IFN-g-secreting T
cells in mice (24). A standard dose of BCG given to unvacci-
nated individuals from the United States (which is not an area
of endemicity) induces both delayed-type hypersensitivity and
IFN-g (27). Further, the IFN-g levels in BCG-sensitized con-
trols from a region that is not an area of endemicity are also
high (47). Although the expression of IFN-g is believed to be
an indicator of protective immunity, active disease is also as-
sociated with IFN-g expression and increased CD81 cells in
the bronchoalveolar lavage (43) and with high levels of IL-10,
but not IFN-g, to M. tuberculosis antigens in pulmonary tuber-
culosis patients (44). In a recent study from Madras, south
India, BCG vaccination of PPD-negative adults did not change
the level of IFN-g or other cytokines studied (13). This sup-
ports our contention that the Mantoux status might be a host
genetics-determined immune response (8, 19, 36).
The present observation that all of the samples produced
PPD-recalled IFN-g irrespective of the vaccination status of
the subject, while only selected responders, mostly among the
BCG scar-negative group and the non-DR2 group, produced
IL-10 and IL-4 indicates an important role for IL-10 and IL-4,
i.e., a role for Th2 polarization in adult pulmonary tuberculosis
pathogenesis. The expression of PPD-recalled IFN-g by all of
the patients and controls may be attributed to environmental
sensitization by specific and nonspecific cross-reacting patho-
gens and microorganisms (4), which may not be of any use in
the presence of IL-4 or IL-10 expression. The present study has
shown that IL-4 or IL-10 expression needs to be relied on to
identify the Th2 or Th1 profile in areas of endemicity. It has
been suggested that IL-10 and IL-4 expression may be one of
the mechanisms to suppress IFN-g-mediated, protective im-
munity (30). IL-10 is a potent inhibitor of T-cell functions,
MHC class II expression, antigen-specific proliferation, and
IFN-g synthesis, and it is inversely correlated to IFN-g in
human tuberculosis (22, 44). In a mouse model, IL-4 influences
the differentiation of Th0 cells into Th2 cells (1), and the M.
tuberculosis antigen lipoarabinomannan is known to specifi-
cally induce IL-4 (11). Studies on gene knockout mice have
shown that IL-10 is an inhibitor of early mycobacterial clear-
ance and that it negatively regulates numerous macrophage
functions and inflammatory responses (30). In humans, IL-4
and IL-10 have been identified during the early course of the
immune response (5, 44), and further, the highest levels of IL-4
and transforming growth factor b, with a concomitant decrease
in IFN-g, have also been identified in advanced tuberculosis
(15).
The increased expression of IL-10 in both the patients and
controls implies that this may be a de novo process, reinforced
by the endemicity of infections. This assumption is supported
by an active depression of IL-10 expression following in vitro
exposure to PPD. It is possible that following the exposure to
a higher concentration of PPD in vitro, the cytokines of the
Th1 arm might be produced, preemptively suppressing the in
vivo sensitized IL-10 expression. A similar observation of de-
creased expression of IL-10 following in vitro exposure to M.
tuberculosis 38-kDa antigen has been made in our laboratory
(S. Shanmugalakshmi, unpublished data). In another study
from south India, IL-10 expression was detectable in the ab-
sence of any in vitro stimulation and was depressed 8 weeks
after BCG vaccination of healthy adults (13). The relative
densities of various M. tuberculosis epitopes may be responsible
for this kind of shift; further in-depth investigation may throw
light on this issue.
Thus, the overall Th1-Th2 paradigm is subject to the dynam-
ics of microbial antigens and their relative densities: once a
Th2 polarization has occurred preemptively, in the absence of
BCG vaccination and with a non-DRB1*02 status, a clinical
disease may follow. It is possible that once the T-helper phe-
notype is determined it might not be further influenced by
related and unrelated antigens, as suggested in the case of
leprosy (29). It is possible that the endemicity of infection,
chronic exposure, and heterologous immunity skew the im-
mune response, facilitating the ability of the infection to over-
whelm the host defenses (17). The underlying mechanism may
be an epitope shift in antigen recognition based on the abun-
dance and persistence of various M. tuberculosis epitopes and
the immunosequestration during various stages of the disease
and exposure. The observation that BCG vaccination was not
able to protect in the lepromatous form of leprosy but was able
to do so in a more unstable borderline form is an example of
this school of thought (43a).
The present observations on the MHC class II (DRB1*)
allele dependence of IFN-g expression in controls but not in
patients suggests that an inherent cytokine expression can be
skewed by the infectious load. Another study employing a
similar whole-blood culture system has also associated many
HLA alleles (HLA DR1, -2, and -6) with high IFN-g produc-
tion and a few others (DR3, -4, -5, and -7) with low IFN-g
production in healthy individuals (34). It is known that in a
mouse model C57BL/6 mice are preferentially IFN-g produc-
ers, while BALB/c mice are preferentially IL-4 producers (31).
It is possible that the MHC-linked cytokine production status
and MHC-presented and antigen- or epitope-specific induc-
tion of cytokines are two different facets of cytokine expres-
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sion, the first one being genetic and a priori and the second one
being immunological.
In conclusion, the present study has indicated an important
role for Th2 cytokines, BCG vaccination status, and MHC class
II-DRB1 allelic polymorphisms in adult pulmonary tuberculo-
sis susceptibility in this environment of endemicity. Decipher-
ing the M. tuberculosis antigens and epitopes skewing the M.
tuberculosis-specific immune responses has become urgent.
Any new-generation vaccine and immunotherapeutics should
induce a sterilizing immunity in patients and high-risk adults
from this region of endemicity (3, 28).
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